HBV-DNA阳性肝癌患者术后动态观察ALT水平变化对病情发展的评估

目的动态观察HBV-DNA阳性肝癌患者术后ALT水平变化对并发症发生的评估及与防治的关系，以期寻找简便指标预测并发症的发生，指导临床实践。方法1998--2005年南通大学附属肿瘤医院收治HBV-DNA阳性HCC肝切除术患者46例，HBV-DNA阴性HCC肝切除术患者36例，所有病例术前进行肝功能评估。分别于术前、术后1d、7d、14d测定血清丙氨酸转氨酶（ALT），PCR法检测HBV-DNA。生化指标均在日立7170A全自动生化分析仪测定。结果HBV—DNA阳性肝切除术后血清ALT水平明显升高，以后逐渐下降接近术前水平，术前后变化差异有统计学意义（P〈0．001）；并发症组各阶段值均高于无并发症组（P〈0．05）；HBV—DNA阴性肝切除术后血清ALT水平也明显升高，以后逐渐下降接近术前水平，术前后变化差异有统计学意义（P〈0．001）；并发症组HBV—DNA阳肝切除术患者与HBV—DNA阴性肝切除患者血清ALT水平显著增高（P〈0．05），而无并发症组HBV-DNA阳性肝切除术患者与HBV-DNA阴性肝切除患者血清ALT水平无显著差异。结论HBV-DNA阳性与否与术后血清ALT增高水平与并发症发生率之间有一定的关系；HBV-DNA阳性肝癌患者术后动态观察ALT水平变化对预测病情发展尤其是并发症的发生有一定的临床价值。     

HBV DNA阳性肝癌患者血清HBeAg检测与肝细胞癌复发转移的关系

目的:研究HBV DNA阳性肝癌(HCC)患者血清HBeAg检测与肝细胞癌复发转移的关系.方法: HBV DNA阳性HCC肝切除术患者60例,HBV DNA阴性HCC肝切除术患者60例.60例HBV DNA阳性HCC患者中依据肿瘤病灶局限、肉眼以及镜下均无肝内播散和门静脉浸润的低侵袭组,共28例;肿瘤组织伴有多发性肝内播散和(或)门静脉主肝癌栓者为高侵袭组,共32例.检测患者术前及术后1周血清HBV DNA水平,观察肝功能变化并检测血清HBeAg水平.结果:HBV DNA阳性组与HBV DNA阴性组比较,60例HBV DNA阳性HCC患者中HBeAg阳性患者为48例,阳性率为80%,60例HBV DNA阴性HCC患者中HBeAg阳性患者为12例,阳性率为20%,(P<0.05).不同侵袭组HBeAg表达比较: 32例高侵袭组中29例HBeAg检测阳性,阳性率为90.62% ,28例低侵袭组中19例HBeAg检测阳性, 阳性率为67.86%,(P<0.05).结论:早期肝癌患者血清HBV DNA和HBeAg可作为肝细胞癌复发转移监测指标.     

对乙肝病毒血清标志物阳性患者化疗所致肝损害的临床观察

目的观察乙肝病毒血清标志物阳性恶性肿瘤患者化疗所致肝功能损害情况.方法乙肝病毒血清标志物阳性恶性肿瘤患者336例,化疗2周后测肝功能(包括ALT、AST、ALP、GGT及TBIL),并选119例乙肝病毒标志物阴性恶性肿瘤患者作为对照.结果乙肝病毒标志物阳性组肝功能异常比率(38.39%)显著高于对照组(19.33%)(P＜0.01).结论乙肝病毒标志物阳性恶性肿瘤患者化疗时较易出现肝功能损害.     

五项肝酶学指标在肝癌诊断上的意义

目的:了解а-岩藻糖苷酶(AFU)、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、γ-谷氨酰转肽酶(GGT)、碱性磷酸酶(ALP)五项肝酶学指标在肝癌诊断中的意义。方法:使用全自动生化分析仪对156例肝病患者和30例正常人血清中五项肝酶学指标进行检测,对检测结果进行统计学分析。结果:原发性肝癌组AFU、ALT、AST、ALP、GGT五项指标均明显增高,其中AFU的血清含量为(39.5±1.76),与转移性肝癌组有差异,与良性肝占位性病变(肝血管瘤、肝囊肿等)有明显的差异P<0.05;原发性肝癌组和转移性肝癌组ALP、GGT均显著增高,与良性肝占位性病变有明显的差异P<0.05;转移性肝癌组血清ALT活性为(132.0±190.7),与原发性肝癌组血清ALT活性(64.0±25.4)相比,明显的增高P<0.05。结论:AFU、ALP、GGT在肝癌的诊断中有较好的应用价值;AFU、ALT在原发性肝癌与转移性肝癌以及良性肝占位性病变的鉴别诊断中有较好的应用价值。     

HBVDNA阳性肝癌患者血清HBeAg检测与肝细胞癌复发转移的关系

目的：研究HBVDNA阳性肝癌（HCC）患者血清HBeAg检测与肝细胞癌复发转移的关系。方法：HBVDNA阳性HCC肝切除术患者60例,HBVDNA阴性HCC肝切除术患者60例。60例HBVDNA阳性HCC患者中依据肿瘤病灶局限、肉眼以及镜下均无肝内播散和门静脉浸润的低侵袭组,共28例;肿瘤组织伴有多发性肝内播散和（或）门静脉主肝癌栓者为高侵袭组,共32例。检测患者术前及术后1周血清HBVDNA水平,观察肝功能变化并检测血清HBeAg水平。结果：HBVDNA阳性组与HBVDNA阴性组比较,60例HBVDNA阳性HCC患者中HBeAg阳性患者为48例,阳性率为80％,60例HBVDNA阴性HCC患者中HBeAg阳性患者为12例,阳性率为20％,（P〈0．05）。不同侵袭组HBeAg表达比较：32例高侵袭组中29例HBeAg检测阳性,阳性率为90．62％,28例低侵袭组中19例HBeAg检测阳性,阳性率为67．86％,（P〈0．05）。结论：早期肝癌患者血清HBVDNA和HBeAg可作为肝细胞癌复发转移监测指标。     

肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响

目的 探讨抑郁对肝癌肝切除患者血清C反应蛋白(CRP)、超敏C反应蛋白(hs-CRP)水平及预后的影响。方法 纳入肝癌行肝切除术患者251例,术前3天使用医院焦虑抑郁量表-抑郁亚量表(Hospital anxiety and depression scale,HADS-D)、9条目患者健康问卷(9-item patients health questionnaire,PHQ9)对患者进行抑郁评估,根据评分结果将患者分为抑郁组(n=95)和无抑郁组(n=156),比较两组患者术前血清CRP、hs-CRP、谷丙转氨酶(ALT)、谷草转氨酶(AST)水平,生存分析Kaplan-Meier法比较两组患者术后无瘤生存期(DFS)和总生存期(OS)。结果 抑郁组患者的血清CRP、hs-CRP、ALT、AST水平均高于无抑郁组(P＜0.05)。随访3.5年结果显示,164例(抑郁组65例,无抑郁组99例)患者出现复发或转移、47例(抑郁组22例,无抑郁组25例)死亡,抑郁组患者DFS、OS均显著低于无抑郁组(P＜0.05)。多因素Cox回归分析显分析显示,肝功能分级、BCLC分期、抑郁是影响肝癌预后的独立危险因素。Spearman相关分析显示,患者抑郁程度与血清CRP、hs-CRP水平呈正相关(P＜0.05),DFS、OS与血清CRP、hs-CRP水平呈负相关(P＜0.05)。结论 抑郁可能介导血清CRP、hs-CRP水平升高,维持患者体内的炎症反应,导致肝功能损伤加重,ALT、AST水平升高,进而对肝癌患者预后造成不良影响。     

慢性乙型肝炎病毒感染者与肝癌家族聚集性患者血清HBsAg和HBV-DNA检测的意义

目的探讨慢性乙型肝炎病毒(HBV)感染者与肝癌家族聚集性(FH)患者体内血清乙型肝炎表面抗原(HBsAg)与HBV基因(HBV-DNA)定量水平检测的意义。方法选取2011年2月至2016年10月间南方医科大学深圳医院收治的55例慢性HBV感染患者为观察组,同时选取63例FH患者为对照组。比较两组患者HBsAg定量水平、HBV-DNA定量水平及肝功能指标。分析HBV-DNA与肝功能指标和HBsAg的相关性。结果观察组患者HBsAg定量水平均值显著高于对照组患者,差异有统计学意义(P<0.05),且乙型肝炎病毒e抗原(HBe Ag)呈阴、阳性患者血清HBsAg定量水平在两组间的平均值比较,差异均有统计学意义(均P<0.01)。观察组患者的HBV-DNA、谷丙转氨酶(ALT)和白蛋白(Alb)水平均显著高于对照组患者,而总胆红素(TBil)水平低于对照组患者,两组比较,差异均有统计学意义(均P<0.05)。两组患者的HBV-DNA与HBsAg定量水平呈正相关性,差异有统计学意义(P<0.05),而与肝功能各项指标均无线性相关性,差异均无统计学意义(均P>0.05)。结论 FH患者的HBsAg水平明显较慢性HBV感染者低,且两者HBsAg定量值与HBV-DNA存在正相关关系。     

原发性肝细胞癌患者外周血单个核细胞中HBV-DNA含量检测的意义

目的:了解原发性肝细胞癌(PHCC)患者外周血单个核细胞(PBMC)中乙型肝炎病毒核酸(HBV-DNA)的整合情况,以揭示其在HCC发病机制中的作用。方法:应用荧光定量聚合酶链反应(FQ-PCR)技术检测32例HCC患者和45例慢性乙型肝炎(CHB)患者血清和PBMC中HBV-DNA含量,引物和探针设计选择HBVC区的DNA序列。结果:HCC组和CHB组患者血清中HBV-DNA阳性率分别为62.5%(20/32)和46.7%(21/45)、HBV-DNA均值(不含阴性)分别为105.50±1.52和105.05±1.45copies/ml,PBMC中HBV-DNA阳性率分别为87.5%(28/32)和51.1%(23/45)(P<0.01)、HBV-DNA均值(不含阴性)分别为104.51±1.32和104.05±1.05copies/ml;HCC组血清和PBMC中HBV-DNA阳性率相比较有统计学差异(62.5%比87.5%,P<0.05);HCC组和CHB组血清和PBMC中HBV-DNA同时阳性时,其HBV-DNA含量均呈正相关(P<0.01)。结论:HCC患者PBMC中存在HBV-DNA整合的现象;作为临床预测HCC发生的风险指标,PBMC中HBV-DNA含量的检测与穿刺肝组织相比具有轻创或无创的优点。     

腹腔镜下解剖性肝切除术对原发性肝癌患者炎症因子、肝功能的影响

目的 探讨腹腔镜下解剖性肝切除术对原发性肝癌患者炎症因子、肝功能的影响。方法 依据手术方式的不同将65例原发性肝癌患者分为对照组（n=33）和观察组（n=32）,对照组患者给予腹腔镜下非解剖性肝切除术,观察组患者给予腹腔镜下解剖性肝切除术,两组患者均给予希望理论干预。比较两组患者的手术相关指标、炎症因子[白细胞介素-10(IL-10)、白细胞介素-8(IL-8)及肿瘤坏死因子-α(TNF-α)]、肝功能指标[丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、总胆红素（TBIL）]及并发症发生情况。结果 观察组患者术后住院时间明显短于对照组,术中出血量、术中输血量均明显少于对照组,差异均有统计学意义（P<0.01）。术后7天,两组患者血清IL-10、IL-8、TNF-α、ALT、AST、TBIL水平均高于本组术前,观察组患者血清IL-10、IL-8、TNF-α、ALT、AST、TBIL水平均低于对照组,差异均有统计学意义（P<0.05）。观察组患者的并发症总发生率为15.63%(5/32),与对照组患者的18.18%(6/33)比较,差异无统计学意义（P>0.05）。结...     

肝细胞癌患者围手术期病毒载量及肝功能变化

目的:探讨肝细胞癌患者围手术期乙肝病毒DNA载量及肝功能的变化。方法:选取2013年4月-2015年4月本院收治的肝细胞癌患者78例作为研究对象。按照术前血清中HBV-DNA载量的不同,将其分为阴性组14例,低复制组48例,高复制组16例。三组患者均行手术治疗,记录三组患者手术前后7天静脉血清中HBV-DNA载量和术后1天肝功能［谷草转氨酶（AST）、谷丙转氨酶（ALT）、总胆红素（TBIL）以及白蛋白（ALB）］变化。结果:手术治疗7天后,阴性组和低复制组患者血清中HBV-DNA载量较治疗前7天有所下降,高复制组患者血清中HBV-DNA载量较治疗前7天有所上升,但无统计学意义（P>0.05）。三组患者手术后的ASL、ALT、TBIL指标较手术前均有明显上升（P＜0.05）,三组术后ALB指标较治疗前下降（P＜0.05）,且阴性组、低复制组、高复制组术后ASL、ALT、TBIL指标比较有递增变化,ALB指标比较有递减变化。结论:肝细胞癌患者行肝癌根除术后仍然存在HBV复制活跃的问题,HBV活跃程度和术前HBV-DNA载量高水平复制会影响到患者术后肝功能恢复。     

原发性与转移性肝癌患者血清学检测的临床应用

  目的  探讨血清学检测指标在鉴别原发性与转移性肝癌时的临床应用价值。  方法  分别测定125例原发性肝癌患者组,135例转移性肝癌患者组及135例无肝转移的癌症患者组血清中ALT、AST、ALP、TBIL、DBIL、GGT、CHE、5'-NT、AFP、CEA、CA199的水平,采用方差析和Scheffe检验进行统计学分析。应用ROC曲线分析AFP、CEA和CA199对原发性肝癌及转移性肝癌的诊断价值。  结果  1）原发性肝癌组与转移性肝癌组之间血清AST、ALP、GGT、5'-NT、AFP及CEA水平差异有统计学意义（P < 0.05）。2）根据原发性肝癌组和转移性肝癌组AFP、CEA和CA199的ROC曲线下面积（Area under the ROC curve,AUC）判断,AFP对原发性肝癌诊断有一定的准确性,CEA、CA199对鉴别原发性肝癌与转移性肝癌有一定诊断价值。  结论  检测血清AST、GGT、5'-NT、AFP、CEA、CA199水平可对恶性肿瘤是否发生肝转移进行初步诊断,亦可对原发性肝癌与转移性肝癌的鉴别诊断提供佐证。      

经皮经肝胆道引流与胆道金属支架置入治疗肝门部胆管癌的疗效分析

目的 对比分析经皮经肝胆道金属支架内引流和导管外引流治疗肝门部胆管癌的疗效和安全性.方法选择肝门部胆管癌患者46 例.按照不同引流方法分为金属支架内引流组27 例和导管外引流组19 例.术后7 天复查两组患者肝功能,记录患者术前术后并发症的发生情况.观察两组患者术后生存情况.结果 两组患者治疗后血清ALT?AST?GGT?ALP?TBiL和DBiL 水平均较术前显著下降,差异有统计学意义(P <0.05);相比于导管外引流组,金属支架内引流组患者ALT?AST?GGT?ALP?TBiL 和DBiL 各指标水平下降更显著,差异有统计学意义(P <0.05).金属支架内引流组患者中位生存时间为12.5 个月,略高于导管外引流组患者的(10.6 个月),但是差异无统计学意义(χ2 =2.531,P =0.112).导管外引流组并发症发生率为31.6%,显著高于金属支架内引流组的11.1%,差异有统计学意义(P<0.05).结论 经皮经肝胆道引流途径金属支架置入姑息性治疗肝门胆管癌的疗效确切,安全性高,优于于经皮经肝胆道导管外引流方法.     

The relationship between the presence and site of cancer,an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study

Background:

Cancer incidence is increasing in the United Kingdom, as well as on a global basis. Biochemical parameters, such as C-reactive protein and albumin (combined to form the modified Glasgow Prognostic Score, mGPS), alkaline phosphatase (Alk phos), γ-glutamyl transferase (GGT) and serum calcium have been reported to be associated with cancer and non-cancer mortality. Therefore, to definitively examine the interrelationships between the above biochemical parameters, the mGPS and the presence of cancer, the Glasgow Inflammation Outcome Study was undertaken. The aim of this initial study was to examine the effect of cancer on markers of systemic inflammation induced by the liver (mGPS) and on levels of routine biochemical parameters.

Methods:

Patients (n=223 303) who had a single incidental sample taken for C-reactive protein, albumin, calcium and serum liver function tests where available, between 2000 and 2008 were studied. Those with a pathological diagnosis of cancer (n=22 715) were identified. The mGPS was constructed and liver function tests classified in accordance with the local reference ranges.

Results:

Patients with cancer had higher C-reactive protein and lower albumin levels (and thus a higher mGPS), higher adjusted calcium, Alk phos and GGT levels, but lower aspartate transaminase (AST) and alanine transaminase (ALT) levels (all P<0.001). The strongest associations (Spearman''s correlation ⩾0.3) in both the non-cancer and cancer groups were found between albumin, C-reactive protein and Alk phos, AST and ALT, AST and GGT and ALT and GGT (all P<0.001). On multivariate analysis, the associations with the presence of cancer remained with age, deprivation, C-reactive protein, albumin, adjusted calcium, Alk phos and GGT (all P<0.01). Patients following a diagnosis of cancer had lower albumin levels and thus higher mGPS (all P<0.001). Also, post-diagnosis patients were more likely to have lower adjusted calcium, bilirubin, Alk Phos, AST, ALT and GGT levels (all P<0.05). When the cancer diagnoses were ranked from those with the lowest proportion of mGPS 1 or 2 to those with the highest, the percentage of cases with a mGPS of 1 or 2 ranged from 21% in breast cancer to 46% in prostate cancer and to 68% in pulmonary cancer. Compared with breast cancer the mGPS was significantly higher in those diagnosed with dermatological, bladder, endocrinological, gynaecological, prostate, musculoskeletal, gastroesophageal, haematological, renal, colorectal, head and neck, pancreaticobiliary and pulmonary cancers (all P<0.001).

Conclusion:

The results of the present study indicate that the systemic inflammatory response is common in a large patient cohort, increased by the presence of cancer and associated with the perturbation of a number of biochemical parameters previously reported to be associated with mortality. There is a striking parallel between the proportions of cases with a mGPS of 1 or 2 and reported survival rates in these tumours.     

肝癌患者血清中黄曲霉毒素白蛋白加合物与肝肾功能的关系

[目的]评价肝癌患者AFB 1-alb加合物的暴露水平以及与肝肾功能的关系.[方法]采用ELISA试剂盒分析82例肝癌患者、31例肝炎患者和51名健康人血清中的AFB1-alb加合物,同时使用全自动生化仪检测不同AFBl-alb加合物水平肝癌患者的肝肾功能,核磁共振成像(MRI)验证肝损伤.[结果] AFB1-alb加合物在肝癌患者血清中的水平高于健康人,两者之间差别有统计学意义(P＜0.05).肝癌和肝炎两组患者之间AFB1-alb加合物水平无明显差异AFB1-alb加合物的暴露水平与身体质量指数有关,而与年龄、性别及居住地无关.血清中的AFB1-alb加合物与总胆红素、谷酰转肽酶、肌酐、尿酸、甘油三脂、胆固醇相关,而与白蛋白、转氨酶、碱磷酶、尿素无明显相关.AFB1-alb加合物高水平组MRI显示脂肪变性的比例高于低水平组(48.8％vs 25.6％),两组之间差异有统计学意义.[结论]肝癌患者血清中的AFB 1-alb加合物高暴露水平影响肝肾功能,AFB1-alb加合物可能成为肝癌诊断的血清学潜在标志物.     

地塞米松预处理降低改良FOLFOX4联合方案致肝功能异常的临床观察

目的观察改良FOLFOX4联合方案辅助地塞米松预处理引起肝功能异常。方法 2010年11月6日前应用改良FOLFOX4联合方案52例患者为对照组,之后的36例改良FOLFOX4联合方案辅助地塞米松预处理的患者为观察组,予以ALT、AST、TBIL、DBIL、ALB、ChE、PA监测。再考证两组患者之间的相关性。结果对照组ALT、AST升高的发生率较观察组高,但差异无统计学意义(P>0.05)。根据化疗周期发生率统计,对照组发生35例,观察组发生8例,组间差异具有统计学意义(P<0.05)。对照组首次出现肝功能异常的时间较观察组有所提前,但差异无统计学意义(P>0.05)。结论在应用改良FOLFOX4联合方案治疗过程中,肝功能损害的发生率较高,而地塞米松在应用过程中发现能有效改善改良FOLFOX4联合方案对肝功能的影响。     

Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma

Hepatitis B virus (HBV) reactivation is well documented in individuals with cancer who receive certain cytotoxic or immunosuppressive therapies including rituximab treatment. As a general rule, the risk is greatest upon withdrawal of chemotherapy. The risk ranges from approximately 20 to 50% among HBsAg-positive carriers. A 67-year-old man was diagnosed with inoperable multiple hepatocellular carcinoma accompanied by an increase in alpha-fetoprotein and protein induced by vitamin K absence or antagonist II level. Eighteen weeks after starting on the oral multi-tyrosine kinase inhibitor TSU-68, laboratory investigations showed a substantial increase in serum transaminase levels (AST: 302 IU/l; ALT: 324 IU/l) and an elevation of the HBV-DNA level (6.9 log copies/ml). The diagnosis was that the cause of the acute hepatitis was HBV reactivation and we immediately administered entecavir. Two months after the initiation of daily entecavir treatment, laboratory findings showed that the serum levels of transaminases and ALP had improved (AST: 18 IU/l; ALT: 10 IU/l; ALP: 197 U/l). When the HBV markers were examined 4 months later, they were altered: HBeAg was negative and HBeAb was positive. Entecavir treatment was discontinued after 6 months. Although reactivation with rituximab has been reported, reactivation with a tyrosine kinase inhibitor is extremely unusual in a patient who is HBsAg negative but anti-HBc positive. This is the first report describing HBV reactivation with an increasing HBV-DNA level in a HBsAg-negative/HBcAb-positive/HBsAb-positive patient who was treated with TSU-68 for hepatocellular carcinoma.Key words: Hepatitis B virus reactivation, Hepatocellular carcinoma, Multi-tyrosine kinase inhibitor     

含奥沙利铂联合方案引起肝功能异常的临床分析

 目的　观察含奥沙利铂联合化疗方案与非奥沙利铂方案对肿瘤患者肝功能的影响。方法　对2005年3月至2007年10月间42例出现化疗药物性肝功能异常的恶性肿瘤患者进行回顾性分析。所有患者均经组织学或细胞学确诊并接受单纯化疗,根据不同的肿瘤类型选择相应的化疗方案,化疗前肝功能均正常,同时排除伴有肝转移、乙肝和丙肝检测阳性、肝硬化等肝脏疾病的病例,其中22例接受含奥沙利铂联合化疗,均采用FOLFOX-4方案,其余20例采用不含奥沙利铂的联合化疗。观察止点为肝功能首次出现异常且在此之前化疗过程中未使用过保肝药物。观察指标包括ALT、AST、 TBIL、DBIL、IBIL、ALP、GGT,同时结合采用WHO不良反应分度标准进行评定。计量资料采用t检验,计数资料采用Wilcoxon秩和检验。结果　全组共接受90个疗程化疗,平均每例接受2.14个周期化疗后出现不同程度的肝损伤。化疗后有13例出现0度肝脏毒性、21例为Ⅰ度、7例为Ⅱ度、1例为Ⅲ度;化疗后以ALT和AST增高更显著（P＜0.05）,其中含奥沙利铂的化疗方案较不含奥沙利铂方案对ALT和AST增高的影响更显著（P＜0.05）,化疗对胆红素无显著影响。两亚组首次出现肝功能异常之前累计化疗疗程数以及不良反应分度的总体分布相似。结论　在保肝药干预之前,含奥沙利铂组较其他化疗方案更易引起肝功能损伤,主要表现为转氨酶的升高。     

Gamma glutamyltransferase,alanine aminotransferase and risk of cancer: Systematic review and meta‐analysis

The prospective evidence for the associations of gamma glutamyltransferase (GGT) and alanine aminotransferase (ALT) with risk of cancer in the general population is uncertain. We conducted a systematic review and meta‐analysis of published prospective observational studies evaluating the associations of baseline levels of GGT and ALT with risk of overall (incidence and/or mortality) and site‐specific cancers. Relevant studies were identified in a literature search of MEDLINE, EMBASE, Web of Science, reference lists of relevant studies to April 2014 and email contact with investigators. Study specific relative risks (RRs) were meta‐analyzed using random effects models. Fourteen cohort studies with data on 1.79 million participants and 57,534 cancer outcomes were included. Comparing top versus bottom thirds of baseline circulating GGT levels, pooled RRs (95% confidence intervals) were 1.32 (1.15–1.52) for overall cancer, 1.09 (0.95–1.24) for cancers of the breast and female genital organs, 1.09 (1.02–1.16) for cancers of male genital organs, 1.94 (1.35–2.79) for cancers of digestive organs and 1.33 (0.94–1.89) for cancers of respiratory and intrathoracic organs. For ALT, corresponding RRs for overall cancer were 0.96 (0.94–0.99) and 1.65 (1.52–1.79) in European and Asian populations, respectively. There was an increased risk of cancers of the digestive organs 2.44 (1.23–4.84). The pooled RR for overall cancer per 5 U/L increment in GGT levels was 1.04 (1.03–1.05). Available observational data indicate a positive log‐linear association of GGT levels with overall cancer risk. The positive association was generally evident for site‐specific cancers. There are geographical variations in the association of ALT and overall cancer.     

腹腔镜肝切除治疗肝脏恶性肿瘤的临床效果

目的：探讨腹腔镜肝切除治疗肝脏恶性肿瘤的临床效果。方法按照手术方式不同将98例肝脏恶性肿瘤患者分为实验组（腹腔镜手术）50例和对照组（开腹手术）48例,比较2组近期疗效。结果实验组患者术中出血量、术后进食时间及住院时间均明显低于对照组,差异有统计学意义（P＜0．05）;实验组患者术中输血率、术后使用杜冷丁率以及术后并发症发生率均明显低于对照组,差异有统计学意义（P＜0．05）。2组患者术后1 d WBC、ALT、AST水平均显著升高,与同组术前比较,差异有统计学意义（P＜0．05）;2组患者术后5 d WBC、ALT、AST水平均显著下降,与同组术后1 d比较,差异有统计学意义（P＜0．05）;实验组患者术后5 d WBC、ALT、AST水平均显著低于对照组,差异有统计学意义（P＜0．05）。结论腹腔镜肝切除治疗肝脏恶性肿瘤创伤小、术中出血量低、使用杜冷丁率低、术后恢复时间短、并发症少,近期疗效显著,可作为临床优选治疗方案。